Nothing Special   »   [go: up one dir, main page]

ZA200003997B - Pharmaceutical compositions. - Google Patents

Pharmaceutical compositions.

Info

Publication number
ZA200003997B
ZA200003997B ZA200003997A ZA200003997A ZA200003997B ZA 200003997 B ZA200003997 B ZA 200003997B ZA 200003997 A ZA200003997 A ZA 200003997A ZA 200003997 A ZA200003997 A ZA 200003997A ZA 200003997 B ZA200003997 B ZA 200003997B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA200003997A
Other languages
English (en)
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200003997(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200003997B publication Critical patent/ZA200003997B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200003997A 2000-01-26 2000-08-04 Pharmaceutical compositions. ZA200003997B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA200003997B true ZA200003997B (en) 2000-08-14

Family

ID=9884259

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200003998A ZA200003998B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions.
ZA200003997A ZA200003997B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200003998A ZA200003998B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions.

Country Status (48)

Country Link
US (2) US6548513B1 (xx)
EP (6) EP2133070A1 (xx)
JP (3) JP3267960B2 (xx)
KR (3) KR100388713B1 (xx)
CN (3) CN1149997C (xx)
AP (2) AP1879A (xx)
AR (3) AR023624A1 (xx)
AT (3) AT412062B (xx)
AU (5) AU6580000A (xx)
BE (2) BE1013413A3 (xx)
BG (4) BG65234B1 (xx)
BR (2) BR0003364A (xx)
CA (3) CA2315141C (xx)
CH (2) CH691347A5 (xx)
CL (1) CL2007001807A1 (xx)
CR (3) CR6568A (xx)
CZ (3) CZ298411B6 (xx)
DE (3) DE60001371T2 (xx)
DK (3) DK178242B1 (xx)
EE (3) EE05221B1 (xx)
ES (2) ES2155043B1 (xx)
FI (3) FI121365B (xx)
FR (2) FR2804025B1 (xx)
GB (3) GB0001621D0 (xx)
HK (6) HK1036934A1 (xx)
HR (3) HRP20020097B1 (xx)
HU (2) HU222578B1 (xx)
IL (4) IL150513A0 (xx)
IS (3) IS1940B (xx)
IT (2) ITTO20000779A1 (xx)
ME (4) ME00202B (xx)
MY (2) MY123650A (xx)
NL (2) NL1015859C2 (xx)
NO (4) NO312434B1 (xx)
NZ (2) NZ531474A (xx)
PL (2) PL341855A1 (xx)
PT (3) PT102503B (xx)
RS (1) RS50201B (xx)
RU (2) RU2264210C2 (xx)
SE (2) SE523471C2 (xx)
SI (1) SI1223918T1 (xx)
SK (2) SK11792000A3 (xx)
TR (3) TR200701171T2 (xx)
TW (2) TWI228050B (xx)
UA (2) UA51853C2 (xx)
WO (2) WO2001054668A1 (xx)
YU (1) YU52902A (xx)
ZA (2) ZA200003998B (xx)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
PT2382970E (pt) † 2000-04-10 2013-02-18 Teva Pharma Composições farmacêuticas estáveis que contêm ácidos 7- substituído-3,5-dihidroxiheptanóicos ou ácidos 7-substituído- 3,5-dihidroxiheptenóicos
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
AU2003254914A1 (en) * 2002-08-12 2004-03-03 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
EP3578175B1 (en) * 2003-09-12 2022-11-30 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
PT1689723E (pt) * 2003-12-02 2011-07-06 Teva Pharma Padrão referência para a caracterização de rosuvastatina
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
ES2606149T3 (es) * 2004-05-04 2017-03-22 Innophos, Inc. Fosfato tricálcico directamente comprimible
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
EP1673351A1 (en) * 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
WO2006091770A2 (en) * 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US7772277B2 (en) * 2005-08-04 2010-08-10 Transform Pharmaceuticals, Inc. Formulations comprising fenofibrate and a statin, and related methods of treatment
JP2008515931A (ja) * 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
JP4955685B2 (ja) 2005-09-12 2012-06-20 アクテリオン ファーマシューティカルズ リミテッド ピリミジン−スルファミドを含む安定な医薬組成物
NZ566872A (en) * 2005-10-31 2010-12-24 Nissan Chemical Ind Ltd Pharmaceutical preparation having excellent photostability containing pitavastatin
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
ES2564250T3 (es) * 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
JP2010523659A (ja) * 2007-04-09 2010-07-15 サイドース・エルエルシー スタチン類と抗肥満症薬との組み合わせ
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
AU2009208610A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of HMG CoA reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
CA2727630A1 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
CA2728539A1 (en) * 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
PL2309992T3 (pl) * 2008-06-27 2018-05-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Kompozycja farmaceutyczna zawierająca statynę
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
WO2011018185A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
CN103648485A (zh) 2011-05-20 2014-03-19 阿斯利康(英国)有限公司 罗苏伐他汀钙的药物组合物
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
MX2015012666A (es) * 2013-03-12 2016-02-16 Lg Life Sciences Ltd Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2016076280A1 (ja) * 2014-11-11 2016-05-19 塩野義製薬株式会社 光に対して不安定な薬物を含有する多層錠剤
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
JP7085473B2 (ja) 2015-10-23 2022-06-16 リンドラ セラピューティクス， インコーポレイティド 治療薬の持続放出用の胃内滞留システム及びその使用方法
CA3007633A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CN110996906A (zh) 2017-06-09 2020-04-10 林德拉有限公司 具有调节释放速度的膜的胃驻留系统
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
ZA891696B (en) * 1988-10-06 1990-11-28 Sandoz Ltd Pyrimidinyl-substituted hydroxyacids,lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DK0475482T3 (da) 1990-09-13 1995-04-03 Akzo Nobel Nv Stabiliserede faste kemiske midler
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
DK0680320T3 (da) 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
NZ324446A (en) * 1995-12-22 1999-08-30 Kowa Co Pharmaceutical composition containing (e)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropyl-quinolin -3'-yl]-6-heptenoic acid where the aqueous solution or dispersion of the composition has a ph of 7 to less than 8
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
DE69925269T2 (de) 1998-06-05 2006-02-23 Warner-Lambert Co. Llc Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
EP2133070A1 (en) 2009-12-16
KR20010077840A (ko) 2001-08-20
FI20001749A (fi) 2001-07-27
SK11782000A3 (sk) 2001-12-03
TWI228050B (en) 2005-02-21
FI20105657A (fi) 2010-06-10
BE1013413A3 (fr) 2001-12-04
RU2264210C2 (ru) 2005-11-20
PT102503A (pt) 2000-12-29
HU0003111D0 (en) 2000-10-28
GB2358582A (en) 2001-08-01
CH691347A5 (de) 2001-07-13
GB2358582B (en) 2004-09-29
IS6480A (is) 2002-07-23
NO2010005I1 (no) 2010-05-03
UA77156C2 (en) 2006-11-15
CA2313783C (en) 2002-03-12
SE0002827D0 (sv) 2000-08-04
FR2795324B1 (fr) 2002-05-17
AR025055A1 (es) 2002-11-06
FI20001749A0 (fi) 2000-08-04
ES2155043B1 (es) 2001-12-01
PT1223918E (pt) 2003-06-30
AU2000264559A1 (en) 2001-08-07
CA2639407A1 (en) 2001-07-26
US6548513B1 (en) 2003-04-15
AU2005202392C1 (en) 2016-06-02
DE60001371T2 (de) 2004-01-22
PL341853A1 (en) 2001-01-29
HRP20020097A2 (en) 2002-06-30
SE523471C2 (sv) 2004-04-20
HRP20020097B1 (en) 2010-12-31
EE05221B1 (et) 2009-10-15
NO327675B1 (no) 2009-09-07
US6316460B1 (en) 2001-11-13
BG66159B1 (bg) 2011-09-30
GB2358583B (en) 2002-02-06
KR20030036492A (ko) 2003-05-09
SE0002827L (sv) 2001-07-27
JP2001206877A (ja) 2001-07-31
GB0019028D0 (en) 2000-09-27
HRP20020632B1 (en) 2010-12-31
PT102503B (pt) 2004-02-27
KR20000072135A (ko) 2000-12-05
IS1940B (is) 2004-07-16
AU781269C (en) 2006-11-30
NL1015859C2 (nl) 2001-10-16
CA2315141C (en) 2009-08-18
CR10114A (es) 2008-08-21
ES2171123B1 (es) 2003-11-16
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
CZ298411B6 (cs) 2007-09-26
EP2266540A1 (en) 2010-12-29
HU0003110D0 (en) 2000-10-28
EE200200052A (et) 2003-04-15
HK1047052A1 (zh) 2003-02-07
IL150513A (en) 2012-12-31
NO20071303L (no) 2001-07-27
NO312434B1 (no) 2002-05-13
HUP0003111A2 (hu) 2002-02-28
ATA13602000A (de) 2004-02-15
HUP0003110A2 (hu) 2001-05-28
NO327554B1 (no) 2009-08-10
MEP33708A (en) 2010-10-10
EE200200411A (et) 2003-12-15
BG106393A (en) 2002-07-31
EP2774609A1 (en) 2014-09-10
CZ290167B6 (cs) 2002-06-12
BG66168B1 (bg) 2011-10-31
IL147870A0 (en) 2002-08-14
HU222578B1 (hu) 2003-08-28
BE1013414A5 (fr) 2001-12-04
RU2002122752A (ru) 2004-03-10
AU5184200A (en) 2001-08-02
ES2155043A1 (es) 2001-04-16
AP2002002591A0 (en) 2002-09-30
BG65234B1 (bg) 2007-09-28
AU781269B2 (en) 2005-05-12
IS8620A (is) 2007-03-07
AR060248A2 (es) 2008-06-04
HRP20020632A2 (en) 2004-12-31
FI20001750A (fi) 2001-07-27
HUP0003110A3 (en) 2003-02-28
EP1223918B1 (en) 2003-02-05
PL196808B1 (pl) 2008-02-29
NO20003968L (no) 2001-07-27
ES2171123A1 (es) 2002-08-16
HK1040936A1 (en) 2002-06-28
DE10038110A1 (de) 2001-08-23
UA51853C2 (uk) 2002-12-16
AU738074B2 (en) 2001-09-06
WO2001054668A1 (en) 2001-08-02
AU6580000A (en) 2001-08-07
EE04990B1 (et) 2008-04-15
ATA13612000A (de) 2004-02-15
FI20001750A0 (fi) 2000-08-04
SE0002826D0 (sv) 2000-08-04
WO2001054669A1 (en) 2001-08-02
CA2315141A1 (en) 2001-07-26
PT102504A (pt) 2001-07-31
FR2804025B1 (fr) 2002-08-23
KR100698333B1 (ko) 2007-03-23
NZ519774A (en) 2004-04-30
JP3267960B2 (ja) 2002-03-25
CR6687A (es) 2005-07-18
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
EP2018853A1 (en) 2009-01-28
BR0003365A (pt) 2001-09-18
AP2002002409A0 (en) 2002-03-31
YU52902A (sh) 2006-01-16
CZ299105B6 (cs) 2008-04-23
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
KR100388713B1 (ko) 2003-06-25
YU5202A (sh) 2004-12-31
PL341855A1 (en) 2001-07-30
MY122707A (en) 2006-04-29
CZ20002884A3 (cs) 2001-09-12
NL1015858C2 (nl) 2001-07-27
DK1223918T3 (da) 2003-04-28
MY123650A (en) 2006-05-31
JP4800988B2 (ja) 2011-10-26
ME00202B (me) 2010-10-10
HK1040936B (zh) 2010-06-11
AU5184100A (en) 2001-08-02
DE10038108A1 (de) 2001-08-02
RS50201B (sr) 2009-07-15
AR023624A1 (es) 2002-09-04
GB0019029D0 (en) 2000-09-27
FR2795324A1 (fr) 2000-12-29
AT412062B (de) 2004-09-27
CN101028268A (zh) 2007-09-05
AU2005202392B2 (en) 2008-11-20
AP1449A (en) 2005-07-28
NO20003968D0 (no) 2000-08-04
CZ20002883A3 (cs) 2000-10-11
DK200001171A (da) 2001-07-27
AP1879A (en) 2008-08-14
TW553749B (en) 2003-09-21
EP1223918A1 (en) 2002-07-24
DK200001170A (da) 2001-01-27
HK1036934A1 (en) 2002-01-25
CA2313783A1 (en) 2000-10-16
DK178242B1 (da) 2015-09-28
BG106926A (bg) 2003-04-30
JP2001206847A (ja) 2001-07-31
DE60001371D1 (de) 2003-03-13
SK283872B6 (sk) 2004-03-02
HK1048950A1 (zh) 2003-04-25
IL150513A0 (en) 2003-02-12
CA2639407C (en) 2011-09-13
CL2007001807A1 (es) 2008-01-18
AT412063B (de) 2004-09-27
NL1015859A1 (nl) 2001-07-27
TR200701171T2 (tr) 2007-04-24
ATE232088T1 (de) 2003-02-15
IL187416A0 (en) 2008-02-09
CN1319396A (zh) 2001-10-31
IS6254A (is) 2002-01-29
GB0001621D0 (en) 2000-03-15
ITTO20000779A0 (it) 2000-08-04
ITTO20000779A1 (it) 2002-02-04
HRP20080525A2 (en) 2008-12-31
SK11792000A3 (sk) 2001-12-03
ZA200003998B (en) 2000-08-14
FI121365B (fi) 2010-10-29
TR200200270T2 (tr) 2002-06-21
JP2007182452A (ja) 2007-07-19
FR2804025A1 (fr) 2001-07-27
HUP0003111A3 (en) 2003-03-28
BR0003364A (pt) 2001-09-18
SE523481C2 (sv) 2004-04-20
SE0002826L (sv) 2001-07-27
TR200201888T2 (tr) 2002-11-21
EE05586B1 (et) 2012-10-15
HK1200368A1 (en) 2015-08-07
NO20003967L (no) 2001-07-27
CH700184B1 (de) 2010-07-15
ITTO20000780A1 (it) 2000-11-04
HK1036935A1 (en) 2002-01-25
CR6568A (es) 2004-03-05
EE200900047A (et) 2011-04-15
IL147870A (en) 2003-10-31
CN1149997C (zh) 2004-05-19
IS2805B (is) 2012-09-15
CN100528161C (zh) 2009-08-19
SI1223918T1 (en) 2003-06-30
NZ531474A (en) 2007-04-27
CN1282581A (zh) 2001-02-07
AU2005202392A1 (en) 2005-06-30
FI111806B (fi) 2003-09-30
DE10038110B4 (de) 2006-06-29
NO20003967D0 (no) 2000-08-04
BG110353A (en) 2009-09-30
EP1251831A1 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
ZA200003997B (en) Pharmaceutical compositions.
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
HUP0300582A3 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
ZA200101012B (en) Pharmaceutical combinations.
ZA200203486B (en) Novel pharmaceutical compositions.
ZA200210359B (en) Pharmaceutical compositions.
HUP0400553A3 (en) Pharmaceutical compositions
MXPA03002105A (es) Composiciones farmaceuticas.
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
ZA200110500B (en) Pharmaceutical composition.
GB0005382D0 (en) Pharmaceutical composition
MXPA03007318A (es) Composicion farmaceutica.
ZA200110501B (en) Pharmaceutical composition.
ZA200110499B (en) Pharmaceutical composition.
ZA200303911B (en) Medicinal compositions.
GB0002691D0 (en) Pharmaceutical composition
GB0000062D0 (en) Pharmaceutical compositions
GB0003929D0 (en) Pharmaceutical compositions
GB0008872D0 (en) Pharmaceutical compositions
HU0700204D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions
GB0031282D0 (en) Pharmaceutical compositions